{"id":18889,"date":"2014-07-12T07:22:19","date_gmt":"2014-07-11T23:22:19","guid":{"rendered":"https:\/\/canadianinquirer.net\/v1\/?p=18889"},"modified":"2014-07-12T00:24:05","modified_gmt":"2014-07-11T16:24:05","slug":"dengue-shot-offers-some-protection-could-prevent-severe-cases-but-safety-questions-remain","status":"publish","type":"post","link":"https:\/\/canadianinquirer.net\/v1\/2014\/07\/12\/dengue-shot-offers-some-protection-could-prevent-severe-cases-but-safety-questions-remain\/","title":{"rendered":"Dengue shot offers some protection, could prevent severe cases but safety questions remain"},"content":{"rendered":"
\"Dengue-carrying<\/a>
Dengue-carrying mosquito. Photo via Top News \/ Flickr.<\/figcaption><\/figure>\n

LONDON\u2014The most advanced vaccine for dengue only offers modest protection but could still help millions of people avoid the devastating effects of the disease known as \u201cbreakbone fever,\u201d according to a large trial.<\/p>\n

There is no treatment for dengue, which causes symptoms including fever, severe joint pain, headaches and bleeding. About half the world\u2019s population is at risk from the mosquito-borne disease, which sickens about 100 million people every year, mostly in Asia, Africa and Latin America.<\/p>\n

Results from an early trial of the vaccine in 2012 found the vaccine\u2019s efficacy was 33 per cent and that it failed to protect against one type of dengue; there are four distinct kinds and the vaccine is meant to fight all of them. In the latest study, conducted in more than 10,000 children aged 2 to 14 in Indonesia, Malaysia, Thailand, the\u00a0Philippines\u00a0and Vietnam, the shot\u2019s efficacy improved to 56 per cent. Most common vaccines like those for measles and polio are more than 95 per cent effective.<\/p>\n

\u201cWe all would have wanted a better efficacy rate but this is what we have to live with at the moment,\u201d said Annelies Wilder-Smith of Nanyang Technological University in Singapore, who wrote a commentary for the study, published Friday in the journal Lancet. \u201cWhether this vaccine\u2019s efficacy is enough for countries to invest in is a question for economists.\u201d<\/p>\n

Researchers tracked the children in the new study, including those who got the fake shot, for about two years and noted side effects and other health problems following the vaccine. The study was paid for by Sanofi Pasteur, the vaccine\u2019s maker.<\/p>\n

Other experts said longer follow-up data on vaccinated children is needed to assess the shot\u2019s safety. People infected with one type of dengue develop antibodies that protect them from further infections of that type. But if they catch another kind of dengue, their antibodies make them susceptible to more serious disease that could include hemorrhaging. Some scientists worry the antibodies from a dengue vaccine might have the same effect and say vaccinated children should be monitored for several years.<\/p>\n

\u201cWe just don\u2019t understand the antibody response in dengue well enough to know if this (problem) would also occur with a vaccine,\u201d said Martin Hibberd, a professor of emerging infectious diseases at the London School of Hygiene and Tropical Medicine, who wasn\u2019t part of the study.<\/p>\n

He was also concerned the shot seemed to work by boosting pre-existing antibodies in people previously infected with dengue, since younger children didn\u2019t get much protection from the shot. \u201cIt\u2019s a bit scary that it looks like the vaccine only works in people who have already had dengue,\u201d which would make the vaccine useless for Western tourists travelling to dengue-endemic countries, he said.<\/p>\n

Officials at Sanofi Pasteur said they plan to apply for regulatory approval starting next year. The company said it was \u201ctoo premature\u201d to discuss the vaccine\u2019s potential price.<\/p>\n","protected":false},"excerpt":{"rendered":"

LONDON\u2014The most advanced vaccine for dengue only offers modest protection but could still help millions of people avoid the devastating …<\/p>\n","protected":false},"author":44,"featured_media":18896,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[37],"tags":[],"class_list":["post-18889","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","mauthors-maria-cheng","mauthors-the-associated-press"],"_links":{"self":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/posts\/18889","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/users\/44"}],"replies":[{"embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/comments?post=18889"}],"version-history":[{"count":0,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/posts\/18889\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/media\/18896"}],"wp:attachment":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/media?parent=18889"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/categories?post=18889"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/tags?post=18889"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}